Lv0
0 积分 2026-03-13 加入
Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis
11小时前
已完结
CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies
15天前
已完结
It’s high TIM-3 for armored CAR-T therapy for B-ALL
15天前
已关闭
A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia
1个月前
已完结
LRIG1 engages ligand VISTA and impairs tumor-specific CD8 + T cell responses
1个月前
已完结
Targeted destruction of VISTA boosts anti-tumor immunotherapy
1个月前
已完结
Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies
2个月前
已完结
Overcoming chimeric antigen receptor-T (CAR-T) resistance with checkpoint inhibitors: Existing methods, challenges, clinical success, and future prospects : A comprehensive review
2个月前
已完结
皖公网安备34019202002308
